These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 21235446)
1. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment. Beck M Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446 [TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). da Silva EM; Strufaldi MW; Andriolo RB; Silva LA Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845 [TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). da Silva EM; Strufaldi MW; Andriolo RB; Silva LA Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699 [TBL] [Abstract][Full Text] [Related]
4. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Whiteman DA; Kimura A Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717 [TBL] [Abstract][Full Text] [Related]
5. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146 [TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). da Silva EM; Strufaldi MW; Andriolo RB; Silva LA Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288 [TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Wraith JE Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193 [TBL] [Abstract][Full Text] [Related]
8. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636 [TBL] [Abstract][Full Text] [Related]
10. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). Burton BK; Jego V; Mikl J; Jones SA J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757 [TBL] [Abstract][Full Text] [Related]
11. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189 [TBL] [Abstract][Full Text] [Related]
12. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience. Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228 [TBL] [Abstract][Full Text] [Related]
13. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry. Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan. Ueda K; Hokugo J Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708 [TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850 [TBL] [Abstract][Full Text] [Related]
17. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS). Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237 [TBL] [Abstract][Full Text] [Related]
19. Mucopolysaccharidosis type II, Hunter's syndrome. Tylki-Szymańska A Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092 [TBL] [Abstract][Full Text] [Related]